NASDAQ · Analyst Forecast

Relmada Therapeutics, Inc. (RLMD) Stock Forecast & Price Target

$3.01 NASDAQ: RLMD Market Cap $321.15M

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Relmada Therapeutics, Inc. (RLMD), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Relmada Therapeutics, Inc., analysts forecast revenue rising from $2.46M in 2025 to $79.78M in 2030; the average estimate for 2030 earnings per share is −$0.42; 4 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$3.01
Consensus targetThe average of the price targets analysts have published.$12.00
Median targetThe middle target, less affected by a single outlier.$12.00
Highest targetThe most optimistic published target.$12.00
Lowest targetThe most pessimistic published target.$12.00
Difference from priceHow far the consensus target sits from today’s price.+298.7%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$2.46M$2.46M$2.46M4
2026$10.00M$10.00M$10.00M3
2027$32.45M$32.45M$32.45M4
2028$12.67M$12.67M$12.67M2
2029$4.90M$4.90M$4.90M1
2030$79.78M$79.78M$79.78M1

Earnings per share forecast

YearLowAverageHighAnalysts
2025−$1.09−$1.05−$1.004
2026−$0.63−$0.62−$0.603
2027−$0.97−$0.80−$0.624
2028−$0.96−$0.74−$0.522
2029−$0.82−$0.82−$0.821
2030−$0.42−$0.42−$0.421

Relmada Therapeutics, Inc. (RLMD) forecast — frequently asked questions

What is the analyst price target for Relmada Therapeutics, Inc.?

Analysts covering Relmada Therapeutics, Inc. (RLMD) have a consensus price target of $12.00, 298.7% above the current price of $3.01. Published targets range from $12.00 to $12.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Relmada Therapeutics, Inc.'s earnings?

The average analyst estimate for Relmada Therapeutics, Inc. (RLMD) earnings per share in 2030 is -0.42, with individual estimates between -0.42 and -0.42.

How much revenue is Relmada Therapeutics, Inc. expected to make?

Analysts forecast Relmada Therapeutics, Inc. (RLMD) revenue of $79.78M in 2030, based on 1 published estimates.

How many analysts cover RLMD?

4 analysts contribute estimates for Relmada Therapeutics, Inc. (RLMD). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.